Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00120939 · ClinicalTrials.gov registry record · Phase 1

Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer

A Phase 1 study of Breast Neoplasms and Prostatic Neoplasms, sponsored by Pharmacyclics.

Completed
Registry status
Phase 1
Development phase
25
Enrollment target
1
Study location

NCT00120939 is a Phase 1 study of Breast Neoplasms and Prostatic Neoplasms that has completed, run by Pharmacyclics. The registered enrollment target is 25 participants, below the 569-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00120939, a Phase 1 study of Breast Neoplasms and Prostatic Neoplasms, has completed, sponsored by Pharmacyclics.

COMPLETED
Registry status
Phase 1
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

The primary purpose of this study is to evaluate the safety, side effects, and dosage for Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced cancers. Secondly, tumor response to the combined treatment, drug levels in the body, and drug interactions will be evaluated.

Conditions Studied

Breast Neoplasms Prostatic Neoplasms Ovarian Neoplasms Lung Neoplasms Gastrointestinal Neoplasms

Interventions

  • DRUG Motexafin Gadolinium

Study Locations (1)

Pennsylvania

  • University of Pittsburgh Medical Center - Pittsburgh

Trial Details

FieldValue
Enrollment Target 25 participants
Phase Phase 1

Sponsor

Pharmacyclics

54 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00120939

The ClinicalTrials.gov registry entry for NCT00120939 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 569-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (96% lower). The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Breast Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Motexafin Gadolinium is the first listed.

NCT00120939 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00120939 about?

NCT00120939 is a clinical study titled "Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer". The primary purpose of this study is to evaluate the safety, side effects, and dosage for Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced cancers. Secondly, tumor response to the combined treatment, drug levels in the body, and drug interactions will be eval...

What is the current status of trial NCT00120939?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants.

What conditions does trial NCT00120939 study?

This clinical trial studies the following conditions: Breast Neoplasms, Prostatic Neoplasms, Ovarian Neoplasms, Lung Neoplasms, Gastrointestinal Neoplasms.

What interventions are being tested in trial NCT00120939?

The interventions under investigation include: Motexafin Gadolinium (DRUG).

Who is sponsoring clinical trial NCT00120939?

This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00120939 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Neoplasms

All registered trials for this condition

Prostatic Neoplasms

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.